Lenvatinib in Anaplastic Thyroid Carcinoma (ATC) in a Tertiary Caner Hospital- a Single Institute Experience

Sharma, Rakesh and Dattatreya, P. S. and Suresh, A. V. S. and Vamsy, Ch Mohana (2021) Lenvatinib in Anaplastic Thyroid Carcinoma (ATC) in a Tertiary Caner Hospital- a Single Institute Experience. Journal of Cancer and Tumor International, 11 (4). pp. 7-10. ISSN 2454-7360

[thumbnail of 197-Article Text-371-1-10-20220913.pdf] Text
197-Article Text-371-1-10-20220913.pdf - Published Version

Download (148kB)

Abstract

Anaplastic Thyroid Carcinoma (ATC) is an aggressive rare form of caner with limited treatment options and short survival. In view of initial case reports have shown some good clinical response with lenvatinib, we used the same in our institute. We are presenting a retrospective series of 4 cases between 2018-2021. It showed very promising results with 75% showing clinically meaningful regression of tumor. Hypertension is the most common side effect, which should be aggressively managed. We feel that, lenvatinib remains a safe and effective option to explore in patients with refractory anaplastic thyroid carcinoma.

Item Type: Article
Subjects: Impact Archive > Medical Science
Depositing User: Managing Editor
Date Deposited: 25 Feb 2023 07:04
Last Modified: 09 Mar 2024 04:03
URI: http://research.sdpublishers.net/id/eprint/895

Actions (login required)

View Item
View Item